# OnCo record asp2138 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/asp2138/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "asp2138" ;
  schema:name "ASP2138"@en ;
  schema:description "ASP2138 is an experimental bispecific antibody from Astellas Pharma Global Development in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2 and CD3."@en ;
  schema:url <https://onco.cc/drugs/asp2138/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=ASP2138>, <https://newsroom.astellas.com/2026-08-25-astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "bispecific antibody" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:targets <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/astellas/> ;
  onco:trials <https://onco.cc/trials/nct07673887/> .